{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:23:09Z","timestamp":1777461789252,"version":"3.51.4"},"reference-count":49,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"unspecified","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pu\u2019er Science and Technology Bureau, China","award":["PEKJ2023001Y"],"award-info":[{"award-number":["PEKJ2023001Y"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["TRR241 A03, WI 3304\/8-1"],"award-info":[{"award-number":["TRR241 A03, WI 3304\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,4,4]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guideline recommends risk stratification for chronic kidney disease (CKD) management; however, patients within the same KDIGO category may still experience heterogeneous outcomes. Hypertension and type 2 diabetes mellitus (T2DM) are predominant causes of CKD, and hepatic fibrosis is highly prevalent in this population, but not integrated into current KDIGO risk assessment. The Fibrosis-4 (FIB-4) index, a widely validated noninvasive marker of hepatic fibrosis, may capture residual risk not reflected by KDIGO stratification. This study aims to explore whether FIB-4 can identify residual risk beyond KDIGO stratification in patients with T2DM and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 1208 patients with T2DM and hypertension. FIB-4 was dichotomized at 1.3 based on established guidelines. The primary outcome was KDIGO high\/very high risk (categories 3\u20134). The secondary outcome was CKD, defined as an estimated glomerular filtration rate &lt;60\u2009mL\/min\/1.73\u2009m\u00b2 and\/or albumin-to-creatinine ratio \u226530\u2009mg\/g. Multivariable logistic regression, restricted cubic spline analysis, and stratified analyses were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1208 patients (mean age 58.3 years; 60.1% male), 514 (42.5%) had FIB-4&gt;1.3, 286 (23.7%) were classified as KDIGO 3\u20134, and 588 (48.7%) met criteria for CKD. After multivariable adjustment, FIB-4&gt;1.3 was independently associated with both KDIGO 3\u20134 (OR 1.57, 95%\u2009CI 1.12 to 2.19, p=0.008) and CKD (OR 1.51, 95%\u2009CI 1.14 to 2.01, p=0.004). In stratified analyses, these associations persisted among patients achieving body mass index\/low-density lipoprotein cholesterol targets, although statistical power was limited for KDIGO 3\u20134. Within KDIGO low-risk categories, elevated FIB-4 was associated with a significantly higher prevalence of vascular comorbidities (p value for trend&lt;0.01 for all). Restricted cubic spline modeling demonstrated a non-linear relationship, with a threshold effect at approximately 1.3 (p value for non-linearity&lt;0.001 for KDIGO 3\u20134; p=0.010 for CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated FIB-4 is independently associated with KDIGO 3\u20134\u2009and CKD, and identifies patients with higher vascular comorbidity burden even within KDIGO low-risk categories. FIB-4 may serve as a complementary risk stratification marker within the KDIGO framework for patients with T2DM and hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-005880","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:15:29Z","timestamp":1777382129000},"page":"e005880","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated FIB-4 index as a risk marker within the KDIGO framework in patients with type 2 diabetes and hypertension"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1455-881X","authenticated-orcid":false,"given":"Hongmei","family":"Fu","sequence":"first","affiliation":[{"name":"Medical Department 1, Friedrich-Alexander-Universitat Erlangen-Nuremberg, Erlangen, Germany"},{"name":"Pu'er People\u2019s Hospital, Pu\u2019er, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhi","family":"Xing","sequence":"additional","affiliation":[{"name":"Pu'er People\u2019s Hospital, Pu\u2019er, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengye","family":"Wang","sequence":"additional","affiliation":[{"name":"Pu'er People\u2019s Hospital, Pu\u2019er, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianwen","family":"Wei","sequence":"additional","affiliation":[{"name":"Pu'er People\u2019s Hospital, Pu\u2019er, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wirtz","sequence":"additional","affiliation":[{"name":"Medical Department 1, Friedrich-Alexander-Universitat Erlangen-Nuremberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026042806150775000_14.2.e005880.1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"The Lancet"},{"key":"2026042806150775000_14.2.e005880.2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dom.15747","article-title":"Cardiovascular and non-renal complications of chronic kidney disease: Managing risk","volume":"26 Suppl 6","author":"Rossing","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026042806150775000_14.2.e005880.3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41440-022-01041-9","article-title":"Impact of hypertension and diabetes on the onset of chronic kidney disease in a general Japanese population","volume":"46","author":"Kaneyama","year":"2023","journal-title":"Hypertens Res"},{"key":"2026042806150775000_14.2.e005880.4","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2023.10.018"},{"key":"2026042806150775000_14.2.e005880.5","first-page":"1266","article-title":"Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis","volume":"330,13","year":"2023","journal-title":"JAMA"},{"key":"2026042806150775000_14.2.e005880.6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.ajkd.2024.08.003","article-title":"KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD","volume":"85","author":"Navaneethan","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"2026042806150775000_14.2.e005880.7","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0094"},{"key":"2026042806150775000_14.2.e005880.8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026042806150775000_14.2.e005880.9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323082"},{"key":"2026042806150775000_14.2.e005880.10","doi-asserted-by":"crossref","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes & Metabolism"},{"key":"2026042806150775000_14.2.e005880.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00519-y"},{"key":"2026042806150775000_14.2.e005880.12","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.7150\/ijbs.100394","article-title":"Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome","volume":"20","author":"Rong","year":"2024","journal-title":"Int J Biol Sci"},{"key":"2026042806150775000_14.2.e005880.13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14072486","article-title":"From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease","volume":"14","author":"Bogdan","year":"2025","journal-title":"J Clin Med"},{"key":"2026042806150775000_14.2.e005880.14","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"2026042806150775000_14.2.e005880.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88285-6","article-title":"High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes","volume":"11","author":"Saito","year":"2021","journal-title":"Sci Rep"},{"key":"2026042806150775000_14.2.e005880.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000677"},{"key":"2026042806150775000_14.2.e005880.17","first-page":"S27","article-title":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025","volume":"48,1 Suppl 1","year":"2025","journal-title":"Diabetes Care"},{"key":"2026042806150775000_14.2.e005880.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24452"},{"key":"2026042806150775000_14.2.e005880.19","doi-asserted-by":"crossref","unstructured":"Touboul P-J , et al . Mannheim intima-media thickness consensuson behalf of the advisory board of the 3rd watching the risk symposium 2004, 13th european stroke conference, mannheim, germany, may 14, 2004. Cerebrovascular diseases; 2004:346\u20139.","DOI":"10.1159\/000081812"},{"key":"2026042806150775000_14.2.e005880.20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.14366\/usg.16054","article-title":"Doppler ultrasonography of the lower extremity arteries: anatomy and scanning guidelines","volume":"36","author":"Hwang","year":"2017","journal-title":"Ultrasonography"},{"key":"2026042806150775000_14.2.e005880.21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2026042806150775000_14.2.e005880.22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.146019"},{"key":"2026042806150775000_14.2.e005880.23","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"2026042806150775000_14.2.e005880.24","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2024-0014"},{"key":"2026042806150775000_14.2.e005880.25","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18136980","article-title":"The Association between Decreased Kidney Function and FIB-4 Index Value, as Indirect Liver Fibrosis Indicator, in Middle-Aged and Older Subjects","volume":"18","author":"Kotoku","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026042806150775000_14.2.e005880.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22636-9","article-title":"Prediction of decreased estimated glomerular filtration rate using liver fibrosis markers: a renal biopsy-based study","volume":"12","author":"Mima","year":"2022","journal-title":"Sci Rep"},{"key":"2026042806150775000_14.2.e005880.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21039-0","article-title":"Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men","volume":"12","author":"Kuma","year":"2022","journal-title":"Sci Rep"},{"key":"2026042806150775000_14.2.e005880.28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.20517\/mtod.2024.07","article-title":"Association of NAFLD\/NASH, and MAFLD\/MASLD with chronic kidney disease: an updated narrative review","volume":"4","author":"Lonardo","year":"2024","journal-title":"Metab Target Organ Damage"},{"key":"2026042806150775000_14.2.e005880.29","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001606"},{"key":"2026042806150775000_14.2.e005880.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026042806150775000_14.2.e005880.31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026042806150775000_14.2.e005880.32","first-page":"226","article-title":"Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine","volume":"22","author":"Stefan","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026042806150775000_14.2.e005880.33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41100-024-00533-3","article-title":"Smoking status, cadmium, and chronic kidney disease","volume":"10","author":"Lang","year":"2024","journal-title":"Ren Replace Ther"},{"key":"2026042806150775000_14.2.e005880.34","first-page":"815","article-title":"Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"2026042806150775000_14.2.e005880.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01605-6"},{"key":"2026042806150775000_14.2.e005880.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"2026042806150775000_14.2.e005880.37","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1007944","article-title":"Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026042806150775000_14.2.e005880.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.01.006"},{"key":"2026042806150775000_14.2.e005880.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-68188-0","article-title":"Hepatokine fibrinogen-like protein 1 drives liver-kidney crosstalk to promote renal fibrosis","volume":"17","author":"Wu","year":"2026","journal-title":"Nat Commun"},{"key":"2026042806150775000_14.2.e005880.40","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330595"},{"key":"2026042806150775000_14.2.e005880.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026042806150775000_14.2.e005880.42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Mellemkj\u00e6r","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026042806150775000_14.2.e005880.43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2337\/dsi23-0014","article-title":"Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2026042806150775000_14.2.e005880.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2026042806150775000_14.2.e005880.45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026042806150775000_14.2.e005880.46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026042806150775000_14.2.e005880.47","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf135","article-title":"SGLT2 Inhibitors Modify Fibrosis-4 Index and Mitigate the Development of DKD: Role of Background Antidiabetic Drugs","volume":"9","author":"Takano","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026042806150775000_14.2.e005880.48","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"},{"key":"2026042806150775000_14.2.e005880.49","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL) . EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024;492\u2013542. doi:10.1016\/j.jhep.2024.04.031","DOI":"10.1016\/j.jhep.2024.04.031"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-005880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:15:36Z","timestamp":1777382136000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-005880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,28]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjdrc-2025-005880"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-005880","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}